CSL Share Price Performance
AU$264.05
-37.05 (-12.30%)
15.5% undervalued intrinsic discount
AU$312.60
Fair Value
Price AU$264.05
AnalystConsensusTarget AU$312.60
Ramsee AU$263.33
Fair ValueAU$312.60
Share PriceAU$264.05
15.5% undervalued intrinsic discount
CSL Community Narratives
AN
Fair Value AU$312.60 15.5% undervalued intrinsic discount
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
2users have liked this narrative
0users have commented on this narrative
107users have followed this narrative
RA
Fair Value AU$263.33 0.3% overvalued intrinsic discount
CSL is undervalued in High Tax Scenario
3users have liked this narrative
4users have commented on this narrative
43users have followed this narrative
CSL Community Fair Values
- AU$312.60FV15.5% undervalued intrinsic discount6.83%Revenue growth p.a.2users have liked this narrative0users have commented on this narrative107users have followed this narrative4 days ago author updated this narrative
- AU$263.33FV0.3% overvalued intrinsic discount6.00%Revenue growth p.a.3users have liked this narrative4users have commented on this narrative43users have followed this narrative4 months ago author updated this narrative
Recent CSL News & Updates
No updates
CSL Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 19, 2025
- Earnings per share (EPS)
- 5.68
- Gross Margin
- 52.23%
- Net Profit Margin
- 18.04%
- Debt/Equity Ratio
- 50.4%
CSL Limited Competitors
About CSL
- Founded
- 1916
- Employees
- 32698
- CEO
- WebsiteView website
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 6.6%
- 1 Year: 8.6%
- Year to Date: 5.1%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.2%. More promisingly, the market is up 8.6% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading